KOSDAQ - Delayed Quote KRW

Genexine, Inc. (095700.KQ)

5,110.00
+350.00
+(7.35%)
At close: 3:30:27 PM GMT+9
Currency in KRW All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
2,932,735.73
2,932,735.73
4,426,626.99
16,139,032.16
36,828,454.64
Cost of Revenue
4,173,466.42
4,173,466.42
4,039,141.93
4,775,970.31
5,021,961.34
Gross Profit
-1,240,730.69
-1,240,730.69
387,485.06
11,363,061.85
31,806,493.30
Operating Expense
35,962,502
35,962,502
41,628,371
45,042,125
50,905,772
Operating Income
-37,203,232.69
-37,203,232.69
-41,240,885.94
-33,679,063.15
-19,099,278.70
Net Non Operating Interest Income Expense
-1,573,436.95
-1,573,436.95
-2,583,425.49
-3,573,739.13
-253,606.94
Pretax Income
-65,411,540.76
-65,411,540.76
-66,860,297.23
-56,831,170.41
-48,561,062.65
Tax Provision
-1,705,666.18
-1,705,666.18
--
--
--
Net Income Common Stockholders
-63,705,874.57
-63,705,874.57
-66,873,517.57
-55,973,927.53
-47,726,585.05
Basic EPS
-1.51k
--
-1.65k
-1.32k
-1.38k
Diluted EPS
-1.51k
--
-1.65k
-1.32k
-1.38k
Basic Average Shares
42,161.40
--
40,480.34
32,644.79
34,689.73
Diluted Average Shares
42,161.40
--
40,480.34
32,644.79
34,689.73
Total Operating Income as Reported
-37,245,760.36
-37,245,760.36
-41,240,886.62
-33,679,063.95
-19,373,191.03
Rent Expense Supplemental
43,753
43,753
--
2,435
34,352
Total Expenses
40,135,968.42
40,135,968.42
45,667,512.93
49,818,095.31
55,927,733.34
Net Income from Continuing & Discontinued Operation
-63,705,874.57
-63,705,874.57
-66,873,517.57
-55,973,927.53
-47,726,585.05
Normalized Income
-64,773,779.40
-64,773,779.40
-70,495,850.57
-84,335,494.53
-37,811,273.05
Interest Income
1,053,274
1,053,274
1,263,871
243,366
219,145
Interest Expense
2,645,033
2,645,033
4,110,901
3,809,903
492,372
Net Interest Income
-1,573,436.95
-1,573,436.95
-2,583,425.49
-3,573,739.13
-253,606.94
EBIT
-62,766,507.76
-62,766,507.76
-62,749,396.23
-53,021,267.41
-48,068,690.65
EBITDA
-57,332,751.76
-57,332,751.76
-57,718,009.23
-48,149,388.41
-44,770,240.65
Reconciled Cost of Revenue
4,173,466.42
4,173,466.42
4,039,141.93
4,775,970.31
5,021,961.34
Reconciled Depreciation
5,433,756
5,433,756
5,031,387
4,871,879
3,298,450
Net Income from Continuing Operation Net Minority Interest
-63,705,874.57
-63,705,874.57
-66,873,517.57
-55,973,927.53
-47,726,585.05
Total Unusual Items Excluding Goodwill
1,096,497
1,096,497
3,622,333
28,361,567
-9,915,312
Total Unusual Items
1,096,497
1,096,497
3,622,333
28,361,567
-9,915,312
Normalized EBITDA
-58,429,248.76
-58,429,248.76
-61,340,342.23
-76,510,955.41
-34,854,928.65
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
28,592.17
28,592.17
0
0
0
12/31/2021 - 9/15/2009

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

9606.HK Duality Biotherapeutics, Inc.
203.400
+4.31%
 
9688.HK Zai Lab Limited
24.950
-1.38%
 
IMAB I-Mab
0.9432
+3.26%
 
9926.HK Akeso, Inc.
85.850
-2.33%
 
1530.HK 3SBIO
19.940
-4.36%
 
NMRA Neumora Therapeutics, Inc.
0.7546
+3.41%
 
JANX Janux Therapeutics, Inc.
24.77
-2.48%
 
ZLAB Zai Lab Limited
32.59
-0.12%
 
ALNY Alnylam Pharmaceuticals, Inc.
292.58
+0.31%
 
AKRO Akero Therapeutics, Inc.
48.35
+1.64%